See also this year's filing and all EDGAR filings for this company.
PDF Report 0001386570_2013_Niagen_Bioscience_Inc.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.19181506650361885, 'aggregate_val': 8986892, 'exp_sum': 11119846, 'exp_to_value': {'AssetsCurrent': 5790699, 'AssetsNoncurrent': 2132954, 'PropertyPlantAndEquipmentNet': 1063239, 'Goodwill': 201650, 'remainder_Assets': 1931304}} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.018571011428415, 'aggregate_val': 9034521, 'exp_sum': 9205476, 'exp_to_value': {'AssetsCurrent': 7927140, 'AssetsNoncurrent': 170955, 'PropertyPlantAndEquipmentNet': 936426, 'Goodwill': 136182, 'remainder_Assets': 34773}} |
Graph
Absolute values for 0001386570, Niagen Bioscience Inc
| xvar | xval | |
|---|---|---|
| 0 | LiabilitiesNoncurrent | 0 |
| 1 | LiabilitiesCurrent | 4,762,959 |
| 2 | remainder_Liabilities | 0 |
| 3 | AssetsCurrent | 7,927,140 |
| 4 | AssetsNoncurrent | 170,955 |
| 5 | PropertyPlantAndEquipmentNet | 936,426 |
| 6 | Goodwill | 136,182 |
| 7 | remainder_Assets | -136,182 |
| 8 | GeneralAndAdministrativeExpense | 23,246,928 |
| 9 | ResearchAndDevelopmentExpense | 0 |
| 10 | remainder_Expenses | -29,006 |
| 11 | remainder_Revenues | 11,610,494 |
| 12 | remainder_NetIncome | -22,978 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Liabilities | 4,762,959 |
| 1 | Assets | 9,034,521 |
| 2 | Expenses | 23,217,922 |
| 3 | Revenues | 11,610,494 |
| 4 | StockholdersEquity | 4,271,562 |
| 5 | NetIncome | -11,630,406 |
| 6 | ComprehensiveNetIncome | -11,630,406 |
| 7 | BaseVar | 24,324,437 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | -0.838 |
| 9 | EconomicCapitalRatio | 0.724 |
Edgar->Model Mapping
Feature Distribution
Change over Time
